Strides Pharma Posts ₹93 Crore Q2 Profit

28 Oct 2024 , 05:13 PM

Strides Pharma reported Q2 FY25 net profit of ₹93 Crore, marking a recovery from a ₹131 Crore loss in the same quarter last year.

Revenue for Q2 FY25 reached ₹1,201 Crore, reflecting a 20.2% growth over ₹999.4 Crore in Q2 FY24. EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.

Total income for Q2 FY25 climbed to ₹1,229.52 Crore, up from ₹1,035.28 Crore year-on-year. Total comprehensive income stood at ₹103.69 Crore, a reversal from a comprehensive loss of ₹156.1 Crore in Q2 FY24.

Operating expenses increased to ₹1,097.98 Crore from ₹984.9 Crore in the same period last year, driven by higher material costs and employee expenses.